DSP216 / Kahr Medical, Thomas Jefferson University - LARVOL DELTA

DSP216 — a novel anti HLA-GxCD47 bi-specific fusion protein for cancer immunotherapy (SITC 2024) - "0155-17-HMO). Samples were received anonymously, and consent was not required.Download figure Open in new tab Download powerpoint Abstract 509 Figure 1"

IO biomarker • Oncology • ANXA5 • CD47 • IL6 • ITGAM • SIRPA • TNFA

DSP216 blocks HLA-G and CD47 signaling toward immune cells and restores anti-cancer activity (ITOC 2024) - "DSP216 prevents HLA-G mediated upregulation of the M2 marker CD163 on macrophages and eliminates HLA-G + CD47 + cancer cells by promoting macrophage-mediated phagocytosis and NK cell-mediated cytotoxicity. DSP216 is a novel bifunctional therapeutic that has the potential to reverse immunosuppressive signaling and unleash innate anti-cancer immune responses."

Immune cell • IO biomarker • Oncology • ANXA5 • CD163 • ITGAM • LILRB1 • LILRB2 • SIRPA

DSP216 blocks HLA-G and CD47 signaling toward immune cells and redesigns the immune suppressive tumor microenvironment (ITOC 2022) - "DSP216 prevents HLA-G mediated polarization of M0 macrophages to M2 macrophages and instead promotes polarization to M1 macrophages. DSP216 is a novel bifunctional Fc-fusion therapeutic that has the potential to reverse tumor suppressive signaling by tumor associated macrophages and unleash the anti-tumor activity of various cells from innate and adaptive immune response."

Biomarker • IO biomarker • Tumor microenvironment • Oncology • CD163 • CD47 • LILRB1 • MRC1 • SIRPA

KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline (PRNewswire) - “Proceeds from the financing will be used to advance clinical development of the Company's lead product candidate, DSP107, a first-in-class CD47x41BB targeting fusion protein for the treatment of solid and blood cancers, through multiple Phase 1/2 studies as well as the development of its preclinical pipeline including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein, through IND-enabling studies.”

Commercial • Hematological Malignancies • Oncology • Solid Tumor

KAHR Announces Exclusive Licensing Agreement with Thomas Jefferson University for Novel Platform of Bi- and Tri-Specific Fusion Proteins for Cancer Immunotherapy (PRNewswire) - “KAHR…announced today that it has entered into a licensing agreement with Thomas Jefferson University -- a national doctoral research university -- and its clinical enterprise, Jefferson Health, located in Philadelphia, PA. Under the agreement, Thomas Jefferson University is granting KAHR an exclusive license to develop and commercialize multiple new drug candidates including DSP502, a TIGITxPD1 fusion protein, and DSP216, a LILRB2xSIRPa fusion protein for immuno-oncology.”

Licensing / partnership • Oncology